1. Home
  2. FINW vs NKTX Comparison

FINW vs NKTX Comparison

Compare FINW & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FINW

FinWise Bancorp

HOLD

Current Price

$13.72

Market Cap

235.7M

Sector

Finance

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$3.34

Market Cap

247.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINW
NKTX
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.7M
247.4M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FINW
NKTX
Price
$13.72
$3.34
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
15.5K
1.0M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
21.51
11.88
EPS
1.13
N/A
Revenue
N/A
N/A
Revenue This Year
$160.48
N/A
Revenue Next Year
$35.27
N/A
P/E Ratio
$12.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.59
$1.63
52 Week High
$22.49
$3.65

Technical Indicators

Market Signals
Indicator
FINW
NKTX
Relative Strength Index (RSI) 27.82 66.48
Support Level N/A $1.88
Resistance Level $18.95 $3.65
Average True Range (ATR) 0.67 0.28
MACD -0.29 0.01
Stochastic Oscillator 15.50 67.15

Price Performance

Historical Comparison
FINW
NKTX

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: